Establishing the prevalence of common, clinically relevant tissue-specific autoantibodies following SARS CoV-2 infection
Alex G. Richter1 , Adrian M. Shields1, Abid Karim1, David Birch1, Sian E. Faustini1, Lora Steadman2, Kerensa Ward 1, Timothy Plant1, Gary Reynolds2, Tonny Veenith3, Adam F. Cunningham2, Mark T. Drayson1, David C. Wraith2
Clinical Immunology Service, Institute for Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
Institute of Immunology and Immunotherapy, University of Birmingham, UK
Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, Birmingham, UK
Key words: COVID-19, SARS-CoV-2, autoimmunity, autoantibodies, Long COVID
Word count:
Number of figures: 2
Number of tables: 2
Supplementary data: 2 tables